Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Healthtrust
Accenture
Farmers Insurance
Chubb
Argus Health
Moodys
Fuji
QuintilesIMS

Generated: April 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,723,606

« Back to Dashboard

Summary for Patent: 5,723,606
Title: Condensed benzazepine derivative and pharmaceutical composition thereof
Abstract:This invention relates to nitrogen-containing aromatic 5-membered ring-condensed benzazepine derivatives represented by the general formula (I) ##STR1## (symbols in the formula have the following meanings; ring B: a nitrogen-containing aromatic 5-membered ring having at least 1 nitrogen atom and optionally one oxygen or sulfur atom, which may optionally have substituent(s), R.sup.1 and R.sup.2 : these may be the same or different from each other and each represents a hydrogen atom, a halogen atom, a lower alkyl group, an amino group which may optionally be substituted by lower alkyl group(s), or a lower alkoxy group, A: a single bond; a group represented by the formula n: 0 or an integer of from 1 to 3, R.sup.3 and R.sup.4 : these may be the same or different from each other and each represents a hydrogen atom, a lower alkyl group (provided that R.sup.3 and R.sup.4 may together form a lower alkylene group having 2 to 7 carbon atoms), and ring C: a benzene ring which may optionally have substituent(s)) and salts thereof; to pharmaceutical compositions which contain these compounds as an active ingredient and to intermediates which are useful in synthesizing these compounds. The compounds of this invention are useful as arginine vasopressin antagonists.
Inventor(s): Tanaka; Akihiro (Ibaraki, JP), Koshio; Hiroyuki (Ibaraki, JP), Taniguchi; Nobuaki (Ibaraki, JP), Matsuhisa; Akira (Ibaraki, JP), Sakamoto; Ken-ichiro (Ibaraki, JP), Yamazaki; Atsuki (Ibaraki, JP), Yatsu; Takeyuki (Ibaraki, JP)
Assignee: Yamanouchi Pharmaceutical Co., Ltd. (Tokyo, JP)
Application Number:08/586,686
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 5,723,606

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Cumberland Pharms VAPRISOL conivaptan hydrochloride INJECTABLE;IV (INFUSION) 021697-001 Dec 29, 2005 DISCN No No ➤ Sign Up ➤ Sign Up Y Y METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH HYPERVOLEMIC HYPONATREMIA ➤ Sign Up
Cumberland Pharms VAPRISOL conivaptan hydrochloride INJECTABLE;IV (INFUSION) 021697-001 Dec 29, 2005 DISCN No No ➤ Sign Up ➤ Sign Up Y Y METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH EUVOLEMIC HYPONATREMIA ➤ Sign Up
Cumberland Pharms VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER conivaptan hydrochloride INJECTABLE;IV (INFUSION) 021697-002 Oct 8, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH HYPERVOLEMIC HYPONATREMIA ➤ Sign Up
Cumberland Pharms VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER conivaptan hydrochloride INJECTABLE;IV (INFUSION) 021697-002 Oct 8, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH EUVOLEMIC HYPONATREMIA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,723,606

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan5-180435Jul 21, 1993
PCT Information
PCT FiledJuly 19, 1994PCT Application Number:PCT/JP94/01183
PCT Publication Date:February 02, 1995PCT Publication Number: WO95/03305

Non-Orange Book US Patents Family Members for Patent 5,723,606

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,856,564 Condensed benzazepine derivative and pharmaceutical composition thereof ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Colorcon
Harvard Business School
McKinsey
US Army
Fish and Richardson
US Department of Justice
Fuji
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.